View : 656 Download: 0
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study
- Title
- Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study
- Authors
- Seong J.-M.; Yee J.; Gwak H.S.
- Ewha Authors
- 곽혜선; 성종미
- SCOPUS Author ID
- 성종미
- Issue Date
- 2019
- Journal Title
- British Journal of Clinical Pharmacology
- ISSN
- 0306-5251
- Citation
- British Journal of Clinical Pharmacology vol. 85, no. 8, pp. 1719 - 1727
- Keywords
- autoimmune diseases; cohort study; dipeptidyl peptidase IV inhibitors; rheumatoid arthritis; type 2 diabetes mellitus
- Publisher
- Blackwell Publishing Ltd
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Aims: To evaluate the real-world effect of dipeptidyl peptidase-4 inhibitor (DPP4i) on the incidence of autoimmune diseases (AD), including rheumatoid arthritis (RA), inflammatory bowel diseases, multiple sclerosis and systemic lupus erythematosus. Methods: We identified new users of DPP4i (n = 497 619) or non-DPP4i (n = 643 165) oral combination therapy between 1 January 2011 and 30 June 2015 among patients with type 2 diabetes mellitus in the Korean national health insurance claims database. Patients were followed from the date of initiation of combination therapy until AD outcome, censoring for treatment discontinuation or switching, death or end of study (31 August 2016). Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for RA, inflammatory bowel diseases, other AD (multiple sclerosis and systemic lupus erythematosus), and the composite of all outcomes were estimated using propensity score (PS)-adjusted Cox model. Results: In the PS-weighted and PS-matched analysis, the risk of incident RA was decreased for DPP4i initiators compared with non-DPP4i initiators (aHR 0.67 [95% CI 0.49–0.92] and aHR 0.72 [95% CI 0.51–1.01], respectively). In both analyses, the risk of incident composite AD was also decreased for DPP4i initiators compared with non-DPP4i initiators (aHR 0.82 [95% CI 0.68–0.99] and aHR 0.76 [95% CI 0.62–0.93], respectively). Conclusions: In this large population-based cohort study, upfront DPP4i combination therapy was associated with a lower risk of composite AD compared with initial non-DPP4i combination therapy. © 2019 The British Pharmacological Society
- DOI
- 10.1111/bcp.13955
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML